NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

CompletedN/A

Sponsor: AstraZeneca

Conditions: Lung Cancer, Biliary Tract Cancer

Countries: South Korea

The objectives of this study are to assess safety and efficacy of Imfinzi (durvalumab) in a real world setting in patients treated with Imfinzi under the approved indication in Korea.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Eligible for Imfinzi treatment according to the approved label
* Provision of signed and dated written informed consent by the patient or legally acceptable representative

Exclusion Criteria:

* Current participation in any interventional trial
* Other off-label indications according to the approved label

Locations (24)

Anyang-si, South Korea, South Korea
Bucheon-si, South Korea, South Korea
Busan, South Korea, South Korea
Changwon, South Korea, South Korea
Changwon-si, South Korea, South Korea
Cheonan, South Korea, South Korea
Chuncheon, South Korea, South Korea
Daegu, South Korea, South Korea
Daejeon, South Korea, South Korea
Goyang-si, South Korea, South Korea
Gwangju, South Korea, South Korea
Hwasun-gun, South Korea, South Korea
Iksan-si, South Korea, South Korea
Incheon, South Korea, South Korea
Jeju-do, South Korea, South Korea
Jeonju, South Korea, South Korea
Pohang-si, South Korea, South Korea
Seongnam-si, South Korea, South Korea
Seoul, South Korea, South Korea
Suwon, South Korea, South Korea
Uijeongbu-si, South Korea, South Korea
Wŏnju, South Korea, South Korea
Yangsan, South Korea, South Korea
Yongin-si, South Korea, South Korea